Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Long-term outcome of patients who receive ketamine during research
Autore:
Lahti, AC; Warfel, D; Michaelidis, T; Weiler, MA; Frey, K; Tamminga, CA;
Indirizzi:
Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Spring Grove Hosp Ctr, Baltimore, MD 21228 USA Univ Maryland Baltimore MD USA 21228 ve Hosp Ctr, Baltimore, MD 21228 USA
Titolo Testata:
BIOLOGICAL PSYCHIATRY
fascicolo: 10, volume: 49, anno: 2001,
pagine: 869 - 875
SICI:
0006-3223(20010515)49:10<869:LOOPWR>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
HEALTHY-VOLUNTEERS; INDUCED PSYCHOSIS; NMDA ANTAGONIST; SCHIZOPHRENIA; MODEL; MEMORY; HUMANS; ASSOCIATION; EXPERIENCE; PET;
Keywords:
schizophrenia; ketamine; symptom provocation; outcome; challenge; research ethics;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Lahti, AC Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Spring Grove Hosp Ctr, White Bldg,POB 21247, Baltimore, MD 21228 USA Univ Maryland WhiteBldg,POB 21247 Baltimore MD USA 21228 28 USA
Citazione:
A.C. Lahti et al., "Long-term outcome of patients who receive ketamine during research", BIOL PSYCHI, 49(10), 2001, pp. 869-875

Abstract

Background: To comprehend the pathophysiology of schizophrenia and to facilitate drug discovery, animal and human models of schizophrenia are necessary. Ketamine, a noncompetitive N-methyl-D-aspartate antagonist, has been used to probe glutamatergic function in normal and schizophrenic volunteers. The,Fe studies and others have provided data consistent with a putative involvement of a glutamatergic dysfunction in the pathophysiology of schizophrenia; however, these studies have also raised concerns about the distress inflicted on patients, the potential for adverse events, and the serious long-term effects that could possibly be induced by symptom-simulating action. Methods: For all patient volunteers (n = 30) who participated in these studies, we reviewed the acute safety during and in the immediate postketamineadministration. Patients available for long-term follow-up (n = 25) were matched to a group of patients (n = 25) who participated in research but didnot receive ketamine. We compared their long-term outcome in terms of psychopathology, the need for psychiatric care, and the amount of antipsychoticmedication required for optimal therapeutic response. Results: There were no serious adverse events in more than 90 ketamine interviews. Distress to patients was minimal, which is shown by the lack of anxiety ratings, Over ct mean follow-up period of 8 months, we found no differences between patients who did and did not receive ketamine on any measures of psychopathology, psychiatric care, or the amount of antipsychotic medication. Conclusions: In a controlled environment and paying close attention to subject safety features, administering subanesthetic doses of ketamine causes no adverse events and little distress tc, schizophrenic volunteers. This stud!, strongly indicates that administering ketamine does not change any aspect of the course of schizophrenic illness. (C) 2001 Society of Biological Psychiatry.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 00:38:48